Decoy Therapeutics Inc.
DCOY
Get informed when a big investor buys or sells
+ FollowMarket Cap$4.92M
Close$
Share Statistics
| Market cap | $4.92 Million |
|---|---|
| Enterprise Value | $-366,926.00 |
| Dividend Yield | $NaN (NaN%) |
| Earnings per Share | $- |
| Beta | - |
| Outstanding Shares | - |
Return
| Return on Equity | -334.41% |
|---|---|
| Return on Assets | -160.53% |
| Return on Invested Capital | -343.94% |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 0.02 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -8.17 |
| Debt to Equity | 0.69 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Salarius Pharmaceuticals Inc
11 employees
CEO: David Arthur Based in Cambridge, Massachusetts, Decoy Therapeutics Inc. is an early-stage biotechnology firm dedicated to tackling critical unmet medical needs. The company employs cutting-edge machine learning and AI technologies, alongside accelera...